The Tax Cuts and Jobs Act changed how businesses handle research and experimental (R&E) expenses. As a result, in the 2022 to 2024 tax years, many small and mid-sized innovative companies felt the cash-flow pinch of mandatory capitalization under Section 174. The impact was especially significant for businesses pursuing SBIR/STTR awards, developing dual-use technologies, or building R&D-intensive products. The change in treatment of R&E expenditures from current period expenses to capitalized assets amortized over five years for domestic work and fifteen for foreign work caused an increase in taxable income even when the business's underlying economics had not improved.

Under the One Big Beautiful Bill Act (OBBBA) and a new Section 174A, that landscape has changed. OBBBA permanently restores immediate expensing of domestic research and experimental expenditures for tax years beginning after December 31, 2024. In practical terms, for calendar-year taxpayers this means 2025 and 2026 (and beyond) domestic R&E costs can again be deducted in the year they are paid or incurred. Foreign research remains subject to the fifteen-year amortization rules under the revised Section 174.

This change is not merely a technical correction. Instead, it represents a material shift in the economics of innovation for companies that perform the bulk of their research inside the United States.

Why the Distinction Between Domestic and Foreign Matters

"Domestic" under the statute tracks the definition used for the research credit: research activities performed within the United States, the District of Columbia, or Puerto Rico. Activities performed outside those locations remain classified under the longer amortization schedule. Companies with mixed domestic and foreign research teams, contract research arrangements, or overseas development partners must carefully segregate costs. Misclassification creates both compliance risk and missed opportunity.

More good news: the restoration to expensing domestic R&D is a permanent change. Congress did not put a sunset on Section 174A. Companies create multi-year plans, investor models, and decide where to locate additional technical talent or facilities, with certainty about how expenditure treatments apply.

Practical Implications for Growing Companies

For companies that had to capitalize large portions of their R&E spend, there is an immediate cash flow improvement. The ability to expense those costs in the current year reduces taxable income and, in many cases, current tax payments. For SBIR/STTR recipients and other early-stage innovators operating near break-even or with limited working capital, it makes a significant difference.

Several operational and compliance considerations follow:

• Transition of prior-year balances. How do you handle the unamortized domestic Section 174 costs from 2022–2024? Generally, these companies can accelerate the amortization. There are several options companies can choose from to handle the unamortized domestic R&E asset. For instance, taxpayers could deduct the remaining balance in the first tax year beginning after 2024, spread it ratably over the first two such years, or continue the original amortization schedule. Modeling the cash-tax impact of each option is essential. Companies should consult with their tax advisor.
• Accounting method changes and elections. Moving to the Section 174A expensing method (or electing the optional 60-month or Section 59(e) amortization) requires attention to the applicable revenue procedures. Automatic change procedures are available in many cases, but documentation and timing matter.
• Interaction with the research credit. OBBBA and tax legislation also adjusted Section 280C coordination rules. Companies claiming the credit must evaluate whether to reduce the deduction or the credit. Restoring full expensing can shift the economics of that election.
• State conformity. Not every state automatically follows the federal change. Some states have already decoupled or delayed conformity. Companies with multi-state footprints must review each jurisdiction's treatment of R&E expenditures for 2025 and 2026 returns.
• Contract research and cost-sharing. Who "incurs" the Section 174A expenditure in collaborative or sponsored research arrangements continues to require careful analysis of financial risk and rights to the research results.

Focus on Systems, Not Just the Deduction

Immediate expensing is valuable only if the underlying cost accounting and project tracking systems can support it. Companies that never properly identified, segregated, and documented their research expenditures under the capitalization regime will find the same weaknesses surface when they attempt to claim full current deductions or support a research and development (R&D) credit claim.

For companies, sound infrastructure remains the foundation for compliance, tax planning,  and cash flow management. Accurate timekeeping, consistent project coding, clear policies distinguishing research from ordinary product development or production support, and contemporaneous documentation are not optional. They are the difference between a clean deduction and an audit exposure.

Funding Implications

The restoration of domestic expensing of research and experimental expenditures removes one artificial barrier that had been distorting investment decisions. It does not, however, eliminate the need for disciplined financial management, compliance readiness, or strategic clarity about where and how the company conducts its research.

For organizations already operating with strong systems that treat federal funding compliance, cost accounting, and tax planning as integrated disciplines rather than after-the-fact exercises, the change is largely positive and relatively straightforward to implement. For those still building that infrastructure, 2026 is an excellent year to close the gaps.

The companies that will capture the greatest long-term benefit are those that view the return of research and experimental cost expensing not as a one-time tax windfall, but as another reason to strengthen the financial and operational systems that support sustainable innovation.